TORONTO--(BUSINESS WIRE)--LEO Pharma Inc. today announced the availability of the Adtralza® (tralokinumab 300 mg/2 mL) pre-filled pen in Canada. Adtralza is currently indicated in patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1
Prior to the introduction of the pre-filled pen, Adtralza was only available in a 1 mL pre-filled syringe. With the new 2 mL pre-filled pen, patients now have another convenient option with half the number of required injections compared to the 1 mL pre-filled syringe.1
“The pre-filled pen simplifies the injection process and can be helpful for those who are uncomfortable with the sight of needles,” said Dr. Chih-ho Hong, M.D., board certified dermatologist working in Greater Vancouver, BC, and national coordinating investigator for ECZTRA 6 trial in Canada. “It also means half the number of required injections. This option can help reduce patient treatment burden significantly.”
“Atopic dermatitis can be difficult to manage, and can feel overwhelming,” said Amanda Cresswell-Melville, Executive Director, Eczema Society of Canada. “More treatment options mean more hope to those impacted by this burdensome condition.”
“We are pleased to offer Canadians with moderate-to-severe AD an additional option with the single-use pre-filled pen,” said Jill Archibald, President and CEO, LEO Pharma Inc., Canada. “LEO Pharma is committed to supporting patients and providing them with options that offer convenience and help meet their treatment goals.”
For patients who prefer the pre-filled syringe, this option will continue to be available in Canada.
About Adtralza® (tralokinumab injection)
Adtralza is a human, monoclonal antibody developed to specifically target the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).1
In Canada, Adtralza is available in a single-use pre-filled syringe (150 mg/1 mL) as well as a single-use pre-filled pen (300 mg/2 mL). Adtralza received approval from Health Canada in October 2021, for the treatment of moderate to severe atopic dermatitis in adults. Subsequently, in February 2023, the indication was expanded to include adolescents aged 12 – 17 years. The pre-filled pen received approval in August 2023.1
For more information, please refer to the Canadian product monograph for Adtralza located here.
About Atopic Dermatitis/Eczema
Eczema is a chronic inflammatory skin condition, characterized by dry skin, with patches that are red and intensely itchy. These patches of eczema may ooze, become scaly, crusted, or hardened. The condition can impact the patient’s quality of life negatively, as symptoms can range mild to severe. While eczema can appear anywhere on the skin, it is commonly found on the flexor areas, such as the bends of the arms and back of the knees.2
Out of the several types of eczema, atopic dermatitis is the most common. Atopy refers to the genetic susceptibility towards eczema, asthma and allergic rhinitis (hay fever). People with AD can also suffer from one of the other atopic diseases. 2
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world.
For more information, please visit www.leo-pharma.ca.
Adtralza® and the LEO Lion logo are registered trademarks of LEO Pharma A/S used under license and distributed by LEO Pharma Inc. Canada.
| ___________________________ |
|
MAT-74087 June 2024
